Incyte and Syndax Announce FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Read more
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by FDA Read more
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Read more
FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults Read more
GSK’s Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer Read more
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 Read more
Servier’s VORANIGO (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma Read more